New study aims to Fine-Tune treatment for bulging eyes
NCT ID NCT05002998
First seen Jan 04, 2026 · Last updated May 11, 2026 · Updated 21 times
Summary
This study looked at how safe and tolerable different lengths of treatment with teprotumumab are for adults with Thyroid Eye Disease (TED), a condition that can cause bulging eyes and discomfort. About 313 participants received the drug for varying durations to see if shorter or longer treatment works better and if some people need a second round. The goal is to find the best dosing schedule to manage the disease while minimizing side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID EYE DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ARNAS Garibaldi - PO Garibaldi-Centro
Catania, Sicily, 95124, Italy
-
ASST dei Sette Laghi - Ospedale Di Circolo E Fondazione Macchi
Varese, Lombardy, 21100, Italy
-
Azienda Ospedaliera Universitaria Federico II
Naples, Campania, 80131, Italy
-
Azienda Ospedaliero Universitaria Pisana - Stabilimento Santa Chiara
Pisa, Tuscany, 56126, Italy
-
Bascom Palmer Eye Institute
Miami, Florida, 33136-1119, United States
-
Casey Eye Institute - OHSU
Portland, Oregon, 97239-3130, United States
-
Centre Hospitalier National D'ophtalmologie Des Quinze Vingts
Paris, 75571, France
-
Hopital Jean Minjoz
Besançon, Doubs, 25030, France
-
Hospices Civils de Lyon - Hôpital Louis Pradel
Bron, Rhône, 69677, France
-
Hospital La Arruzafa
Córdoba, Córdoba, 14012, Spain
-
Hospital Universitario Ramon y Cajal
Madrid, 28034, Spain
-
Hospital Universitario Virgen Macarena
Seville, 41009, Spain
-
Hôpital Claude Huriez-Lille-Rue Michel Polonovski
Lille, 59000, France
-
Imperial College Healthcare NHS Trust - PPDS
London, London, City of, W21 1NY, United Kingdom
-
Mayo Clinic - PPDS
Rochester, Minnesota, 55905-0001, United States
-
Moorfields Eye Hospital - PPDS
London, London, City of, EC1V 2PD, United Kingdom
-
Royal Victoria Infirmary
Newcastle upon Tyne, Tyne and Wear, NE7 7DN, United Kingdom
-
Southampton University Hospitals NHS Trust
Southampton, SO16 9YD, United Kingdom
-
Stanford University
Palo Alto, California, 94303-3216, United States
-
The Private Practice of Raymond Douglas, MD - Beverly Hills
Beverly Hills, California, 90210-5192, United States
-
USC Roski Eye Institute - Los Angeles
Los Angeles, California, 90033, United States
-
University Hospital of Cardiff
Cardiff, South Glamorgan, CF11 0SN, United Kingdom
-
University Medicine Göttingen Germany
Göttingen, Lower Saxony, 37075, Germany
-
University of Colorado - Eye Center - PPDS
Aurora, Colorado, 80045-2517, United States
-
Universitätsklinikum Essen
Essen, 45122, Germany
-
Universitätsklinikum Münster
Münster, 48149, Germany
-
Universitätsklinikum Tübingen
Tübingen, Baden-Wurttemberg, 72076, Germany
-
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Mainz, Rhineland-Palatinate, 55131, Germany
Conditions
Explore the condition pages connected to this study.